Bone Biologics Corporation
BBLG
$0.6899
$0.02393.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.12% | 0.54% | 2.34% | 31.75% | 20.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.25% | -59.98% | -43.02% | 17.33% | 157.24% |
| Operating Income | 55.25% | 59.98% | 43.02% | -17.33% | -157.24% |
| Income Before Tax | 54.04% | 36.35% | 11.81% | -35.51% | -502.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.04% | 36.35% | 11.81% | -35.51% | -502.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.04% | 36.35% | 11.81% | -35.51% | -502.77% |
| EBIT | 55.25% | 59.98% | 43.02% | -17.33% | -157.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.77% | 84.75% | 86.14% | 81.43% | -69.73% |
| Normalized Basic EPS | 95.38% | 90.15% | 87.36% | 82.56% | -67.49% |
| EPS Diluted | 92.77% | 84.75% | 86.14% | 81.43% | -69.73% |
| Normalized Diluted EPS | 95.38% | 90.15% | 87.36% | 82.56% | -67.49% |
| Average Basic Shares Outstanding | 382.17% | 370.24% | 424.71% | 762.58% | 560.05% |
| Average Diluted Shares Outstanding | 382.17% | 370.24% | 424.71% | 762.58% | 560.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |